Turbine.AI

Turbine is an AI-driven virtual biology company focused on accelerating drug discovery and enhancing clinical translatability. By virtualizing biological experiments, Turbine enables pharmaceutical and biotech partners to simulate millions of experiments in hours, generating mechanistic insights that improve decision-making across the entire drug development pipeline.

Turbine's core technology — the Simulated Cell — models biological mechanisms at scale, allowing researchers to understand not just whether something works, but why. The platform supports a wide range of drug discovery and development use cases, from early target identification through to clinical positioning, and is designed to integrate seamlessly into existing R&D workflows.

Key Use Cases and Decision Support Areas

• Target Discovery: Identify and de-risk novel drug targets, including those with first-in-class potential, using biology-driven insights.
• Combination Design: Simulate and evaluate drug combination strategies to identify synergistic opportunities.
• ADC Positioning: Select and position antibody-drug conjugate payloads using in silico prediction tools.
• Biomarker Selection: Identify relevant biomarkers to support precision medicine approaches.
• Clinical Positioning: Inform clinical strategy with mechanistic simulation data to improve translatability.
• Indication Expansion: Explore new therapeutic indications for existing or pipeline assets.

Virtual Lab Products and Modules

• vLab Core: A self-serve simulation environment built on public and Turbine's proprietary datasets, covering over 1,400 oncology cell lines, 1,200 payloads, drugs, and drug-like molecules, and knockout alterations across more than 8,500 genes. Includes a robust interpretation toolkit for filtering and analyzing in silico results.
• vLab Custom: Enables in silico predictions leveraging a partner's proprietary datasets combined with Turbine's scientific expertise. Partners can add their own sample libraries and drugs, and access interpretation services tailored to their needs.
• vLab Collaborate: A collaborative simulation environment built on virtual endogenous disease models, supporting single or multi-cell samples across most endogenous diseases. Accommodates any relevant chemical or biological therapies and provides a simulations platform adapted to specific use cases, enabling collaborative analysis and interpretation of results across a partner's portfolio.
• ADC Payload Selector: A dedicated module within the Virtual Lab for identifying and selecting optimal ADC payloads.
• Target Discovery and De-Risking: A specialized module supporting systematic identification and validation of novel drug targets.
• Simulate Any Endogenous Disease: Broad disease modeling capability enabling simulation across a wide range of disease contexts.

Platform Performance and Capabilities

• Capable of simulating up to 50 million experiments per day, compressing timelines dramatically.
• Mechanistic hypotheses generated by the platform have been shown to increase the likelihood of experimental validation by 1.5 times.
• The timeline from scientific question to the start of validation is reduced by approximately 2 times, halving the typical research cycle.
• Wet lab-in-the-loop approach: in silico predictions are validated in the wet lab, and resulting experimental data is fed back into the Virtual Lab to continuously improve simulation predictivity.
• Platform is available in both self-serve and workflow-integrated configurations to suit different organizational needs.

Partners, Investors, and Industry Recognition

• Turbine has received investment and partnership support from notable organizations including MSD Global Health Innovation Fund and Accenture Ventures.
• Ono Pharmaceutical has partnered with Turbine, with their Corporate Officer noting that Turbine provided multiple targets with first-in-class potential alongside biology-driven insights for rapid validation.
• Industry leaders from AstraZeneca have recognized Turbine's potential to fundamentally change how novel targets in precision oncology are identified.
• Accenture Ventures has highlighted the platform's demonstrated ability to unlock high-quality biological insights for clients across the biopharma industry.
• Turbine has recently advanced its Virtual Biology capabilities through new financing and an immunology partnership, expanding its reach beyond oncology.
• The company hosts a Virtual Biology Community, bringing together leading scientists and researchers to advance the field.

Turbine's Virtual Lab represents a new paradigm in preclinical research, combining AI-powered simulation with wet lab validation to give biopharma partners the mechanistic understanding and decision-making confidence needed to advance the right programs faster and with greater probability of clinical success.